Latest Breaking News On - Hepcidin mimetic peptide - Page 1 : vimarsana.com

Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics Inc. have inked a global development and commercialization deal worth up to $1.7 billion for Protagonist’s rusfertide for treatment of polycythemia vera (PV), a rare and chronic blood disorder affecting bone marrow.

Protagonist therapeutics incTakeda pharmaceutical coTakeda pharmaceuticalProtagonist therapeuticsTakeda pharmaceutical co ltdProtagonist therapeutics incPolycythemia veraBone marrowHepcidin mimetic peptideDeals andm amp aAsia pacificBioworld asia